Sylvia Qu is a highly accomplished Sr. Principal Scientist at Boehringer Ingelheim, where she leverages her extensive expertise in process chemistry to drive innovation in drug development. With a strong focus on efficient catalytic processes, Sylvia has made significant contributions to the advancement of pharmaceutical...
Sylvia Qu is a highly accomplished Sr. Principal Scientist at Boehringer Ingelheim, where she leverages her extensive expertise in process chemistry to drive innovation in drug development. With a strong focus on efficient catalytic processes, Sylvia has made significant contributions to the advancement of pharmaceutical research and development. Her role involves leading multidisciplinary projects aimed at synthesizing multi-kilo drug substances for toxicology and clinical studies, ensuring that these compounds meet stringent regulatory standards.
One of Sylvia's key projects involved the design and optimization of scalable and cost-effective processes for Active Pharmaceutical Ingredients (APIs). By employing her deep understanding of organic chemistry and advanced techniques such as High-Performance Liquid Chromatography (HPLC), she has successfully streamlined production workflows, enhancing both yield and purity. Her collaborative approach fosters effective communication across various departments, including Medicinal Chemistry, Analytical Chemistry, Solid State Crystallization, and DMPK, ensuring that all aspects of drug development are aligned with the overall project goals.
Sylvia's commitment to excellence is further demonstrated through her adept navigation of Good Manufacturing Practices (GMP) and her proactive engagement with Quality Assurance/Quality Control (QA/QC) and CMC regulatory affairs. This comprehensive skill set not only positions her as a leader in the pharmaceutical industry but also underscores her passion for advancing drug discovery and development processes. As she continues to push the boundaries of process research, Sylvia remains dedicated to delivering innovative solutions that ultimately improve patient outcomes.
